Welcome to our dedicated page for Caris Life Sciences news (Ticker: CAI), a resource for investors and traders seeking the latest updates and insights on Caris Life Sciences stock.
Caris Life Sciences, Inc. (NASDAQ: CAI) is a patient-centric, next-generation AI TechBio company and precision medicine pioneer whose news flow centers on molecular profiling, precision oncology and data-driven healthcare. Company announcements highlight developments in its comprehensive molecular profiling services, financial results, research collaborations and precision oncology network activities.
Investors and healthcare professionals following CAI news can expect updates on revenue trends and clinical therapy selection case volumes related to molecular profiling services and pharma research and developmental services, as reported in the company’s earnings releases. Caris also issues news on partnerships, such as its collaboration through Caris Discovery with Genentech to identify and validate novel oncology targets in solid tumors, and its partnership with Everlywell to launch the Caris Detect Multi-Cancer Early Detection blood-based screening assay.
Caris frequently reports on activities of the Caris Precision Oncology Alliance, a global network of cancer centers, academic institutions, research consortia and healthcare systems focused on advancing precision oncology and biomarker-driven research. News items include new member institutions joining the alliance, educational initiatives like the Caris POA Fellows Forum, and research presented at major conferences, including multi-study presentations at oncology symposia.
This CAI news page aggregates these press releases and related updates so readers can review company communications on financial performance, collaborations, research output and precision oncology programs in one place. For those tracking the evolution of Caris’ molecular profiling platform, clinico-genomic data assets and AI-driven oncology initiatives, this feed offers a consolidated view of the company’s reported milestones and activities.
Caris Life Sciences (NASDAQ: CAI) published a peer-reviewed study validating an AI-derived signature that predicts MGMT promoter methylation and temozolomide (TMZ) benefit in glioblastoma (GBM) patients.
The signature was developed from a clinico-genomic dataset of 5,841 patients and evaluated prospectively in >3,400 cases, showing high concordance with pyrosequencing and stratifying overall survival in TMZ-treated, IDH-wild type GBM.
Caris Life Sciences (NASDAQ: CAI) will present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Presentations: May 12, 2026, 10:00–10:30 AM PT (BofA, Las Vegas) and June 8, 2026, 10:40–11:15 AM ET (Goldman Sachs, Miami). Live and replay webcasts will be available on the company investor relations website.
Caris Life Sciences (NASDAQ: CAI) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. A live webcast will begin at 3:30 p.m. CT (4:30 p.m. ET) to discuss results, with a replay posted on the company investor relations website shortly after the call.
Caris Life Sciences (NASDAQ: CAI) announced on April 17, 2026 that the UCSF Helen Diller Family Comprehensive Cancer Center joined the Caris Precision Oncology Alliance (POA). The membership expands collaborative, biomarker-driven research using Caris' AI-driven multimodal database and comprehensive molecular profiling to support personalized cancer care.
Caris Life Sciences (NASDAQ: CAI) announced expansion of its Right-In-Time (RIT) clinical trial solution to bring biomarker-driven trials to community oncology sites nationwide.
The program spans >600 locations, 2,200 investigators and identified >71,000 patients for possible trial participation, using comprehensive WES/WTS/IHC profiling and a trial-matching workflow that can enroll patients in ~2 weeks (as few as 5 days).
Caris Life Sciences (NASDAQ: CAI) launched a multimodal AI-driven molecular signature to guide first-line treatment selection for a subset of PD-L1 ≥50% non-small cell lung cancer (NSCLC) patients.
The signature uses Whole Exome Sequencing, Whole Transcriptome Sequencing and clinical data via the proprietary CodeAI platform to predict which patients benefit from adding chemotherapy versus those harmed by it. Caris notes the insight is proprietary and available to Caris customers; the company previously received FDA approval in November 2024 for its WES/WTS tissue assay MI Cancer Seek.
Caris Life Sciences (NASDAQ: CAI) launched Caris ChromoSeq on April 2, 2026: a combined Whole Genome Sequencing (WGS) and Whole Transcriptome (WTS) assay for myeloid malignancies.
The test delivers ~250x genome read depth, 40 million transcriptome reads, supports bone marrow or peripheral blood samples, and has an expected seven-day turnaround.
Caris Life Sciences (NASDAQ: CAI) finalized Achieve 1 results for Caris Detect, a multi-cancer early detection test using Whole Genome Sequencing. The study enrolled 3,014 evaluable subjects and reported overall Stage I–II sensitivity ~60.3% and high specificities (asymptomatic 99.2%, benign/high-risk 96.0%). Stage-specific sensitivity ranged from 56.8% (Stage I) to 98.6% (Stage IV).
The company emphasized WGS superiority over methylation-only approaches and plans to add additional pillars, including Whole Transcriptome Sequencing, to improve performance.
Caris Life Sciences (NASDAQ: CAI) added two proprietary Caris AI Insights signatures predicting brain metastases risk in breast cancer and non-small cell lung cancer (NSCLC), bringing its total to seven.
The signatures were trained on 12,994 NSCLC and 3,371 breast cases and use WES/WTS data; MI Cancer Seek orders include the report at no extra cost. Caris reports its multimodal dataset exceeds 500,000 patients tested and notes an ongoing study with the Caris Precision Oncology Alliance to highlight the risk‑prediction approach.
Caris Life Sciences (NASDAQ: CAI) will present six oncology studies at the AACR Annual Meeting, April 17-22, 2026, in San Diego. The posters use Caris' multimodal database (WES, WTS, IHC, real-world clinical data) across breast, prostate, lung and colorectal cancers.
Research highlights will be onsite at booth #1423; full abstracts follow the presentations on the company website.